OneTouch Vibe Plus Insulin Pump and Continuous Glucose Monitoring (CGM) System approved by FDA and Health Canada for monitoring and treatment of diabetes- Animas Corp/J&J

Animas Corporation, part of the Johnson & Johnson Diabetes Care Companies, announced that it has received FDA approval, and Health Canada's authorization for the sale of the OneTouch Vibe Plus Insulin Pump and Continuous Glucose Monitoring (CGM) System for the treatment of patients age two and older living with diabetes.

In addition to being the only Dexcom G5 integrated system cleared by regulatory authorities, it also remains the only integrated system approved for children as young as age two. The enhanced connectivity enables parents and caregivers to continuously access their children's blood glucose to help make treatment choices.